RE:Chronic undervaluation FDA fast track does not mean anything. A proof of concept does not need 2 years to proven . Big pharmas know that. If Nash program is of interest the big pharmas who sit on billions of dollars due to COVID pandemic will jump in. Marathon line of credit is not at risk even if the oncology program fails because TH still have revenue from the legacy drug.
the market is giving the right price to the share in the current context of economy where the stock market has lost 30%. Once we go through this stress the SP will gain 30% which reflects its real value, around $3,5